Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. reports developments for a clinical-stage biotechnology business focused on small-molecule therapeutics for serious viral diseases. Its recurring updates center on investigational antiviral candidates for herpes simplex virus, hepatitis delta virus and hepatitis B virus, including helicase-primase inhibitors ABI-5366 and ABI-1179, the HDV entry inhibitor ABI-6250 and the HBV capsid assembly modulator ABI-4334.
Company news also covers clinical data presentations, financial results, research and collaboration revenue, the Gilead collaboration and licensing activity, and equity financing transactions that support pipeline development.
Assembly Biosciences (Nasdaq: ASMB) announced senior management will participate in fireside chats at two upcoming investor conferences.
The company will present at the Jefferies 2026 Global Healthcare Conference on June 3, 2026 at 4:20 p.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 8:40 a.m. ET. Live webcasts and replays will be available on Assembly Bio’s investor relations website.
Assembly Biosciences (Nasdaq: ASMB) closed its underwritten registered offering of 3,924,624 common shares at $26.50 per share, including full exercise of underwriters’ option for 566,040 additional shares.
The company also sold pre-funded warrants for 415,000 shares, raising approximately $115 million in gross proceeds to fund clinical pipeline development and general corporate purposes.
Assembly Biosciences (Nasdaq: ASMB) priced a registered underwritten offering of approximately $100 million in common stock and pre-funded warrants. The deal covers 3,358,602 shares at $26.50 each and 415,000 pre-funded warrants at $26.499, plus a 30-day option for 566,040 additional shares.
All securities are offered by the company, with closing expected around May 26, 2026. Proceeds are planned to fund clinical development of pipeline candidates and general corporate purposes. Participants include new and existing healthcare-focused investors such as Gilead Sciences and several specialist funds.
Assembly Biosciences (Nasdaq: ASMB) plans to expand development of ABI-6250, an oral NTCP inhibitor for chronic HDV, into cholestatic liver diseases PBC and PSC. A Phase 2 HDV trial is planned for Q4 2026 and a Phase 2 basket study in PBC/PSC for Q1 2027, pending regulatory input.
According to Assembly Bio, Phase 1a data showed target engagement with dose‑dependent increases in plasma bile acids, and chronic toxicology studies support longer-term dosing. ABI-6250 remains investigational, with safety and efficacy not yet established.
Assembly Biosciences (Nasdaq: ASMB) will present topline Phase 1a data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, at the EASL Congress 2026 in Barcelona on May 27, 2026.
The randomized, blinded study evaluates safety, pharmacokinetics and pharmacodynamic activity in healthy participants.
Assembly Biosciences (Nasdaq: ASMB) announced that chief medical officer Anuj Gaggar, MD, PhD, will present at the BofA Securities 2026 Global Health Care Conference at 4:35 p.m. PT on May 13, 2026. A live webcast and replay will be available via the company’s investor relations website.
Assembly Biosciences (Nasdaq: ASMB) reported Q1 2026 results and program updates on May 7, 2026. Key development milestones include completed Phase 1b follow-up for ABI-5366 and ABI-1179, completed chronic toxicology for ABI-6250, and an expected Phase 2 start for ABI-6250 in Q4 2026.
Financials: $226.6M cash and marketable securities at March 31, 2026, projected runway into 2028; collaborative revenue with Gilead was $8.2M in Q1; net loss attributable to common stockholders was $9.1M (loss per share $0.54).
Assembly Bio (Nasdaq: ASMB) announced that positive Phase 1b data for two investigational HSV helicase-primase inhibitors, ABI-5366 and ABI-1179, will be presented at ESCMID Global 2026 in Munich, April 17-21, 2026.
ABI-5366 is selected for an oral presentation (April 20, 2026) and two posters (April 18, 2026). ABI-1179 is a late-breaker poster (April 21, 2026). Posters will be posted on the company website. Both candidates are investigational and exclusively licensed to Gilead for further development.
Assembly Biosciences (Nasdaq: ASMB) reported year-end 2025 results and pipeline progress on March 19, 2026. Key items include a $35 million net option fee from Gilead for the HPI program, $248.1M cash and securities, collaboration revenue of $72.3M, and a net loss of $6.1M for 2025.
Major development milestones: positive Phase 1b data for ABI-5366 and ABI-1179, initiation plans for ABI-6250 Phase 2 by end-2026, and regained rights to ABI-4334 after Gilead declined its option.
Assembly Biosciences (NASDAQ:ASMB) and Gilead Sciences announced Gilead exercised its option to exclusively license Assembly Bio’s HSV helicase-primase inhibitor programs, ABI-1179 and ABI-5366, for recurrent genital herpes on December 22, 2025. Assembly Bio will receive a $35 million payment reflecting an option fee net of prior accelerated funding. Gilead gains sole U.S. development and commercialization rights; Assembly Bio remains eligible for up to $330 million in milestones plus tiered royalties and a U.S. opt-in to share 40% of costs and profits.
Both candidates showed positive Phase 1b antiviral and safety data supportive of once-weekly oral dosing.